RO8994 is primarily investigated for its potential therapeutic application in the treatment of respiratory diseases, particularly chronic obstructive pulmonary disease (COPD) and asthma. It functions as a potent and selective antagonist of the prostaglandin E2 receptor EP4 subtype, which plays a key role in airway inflammation and bronchoconstriction. By blocking this receptor, RO8994 helps reduce inflammatory responses in the lungs, decrease mucus secretion, and promote bronchodilation. Its high selectivity minimizes off-target effects, making it a promising candidate for long-term management of chronic respiratory conditions. Preclinical studies have shown improved lung function and reduced airway hyperresponsiveness, supporting its development as an inhaled or oral agent for anti-inflammatory therapy in pulmonary medicine.